secwatch.observer — SEC 8-K summary
======================================

Issuer:     CytoDyn Inc. (CYDY)
CIK:        0001175680
Form:       8-K
Filed at:   2023-12-14T23:59:59+00:00
Accession:  0001558370-23-019804
Event type: regulatory
Sentiment:  neutral
Materiality: 0.70
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

CytoDyn: FDA lifts partial clinical hold, imposes new full hold on revised protocol; expects January 2024 submission
--------------------------------------------------------------------------------

- Partial clinical hold from March 2022 lifted by FDA in December 2023.
- New full clinical hold placed on proposed HIV trial protocol submitted November 2023.
- Company to incorporate FDA feedback and submit amended protocol by January 2024.
- Views partial hold resolution as significant step; full hold expected resolved after response.
- Proposed HIV study aims to establish leronlimab's mechanism of action cost-effectively.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1175680/000155837023019804/0001558370-23-019804-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1175680/000155837023019804/cydy-20231214x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-019804

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer